drugset / Trial / NCT02584465
REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression
RandomizedParallel-groupOpen-labelTreatment
Summary
The objective of this randomized phase II is to evaluate the benefit of regorafenib for ovarian patients who reported a confirmed elevated CA-125 level under surveillance or bevacizumab, compared with tamoxifen.
Timeline
- Start
- 2015-08-28
- Primary completion
- 2021-09-19
- Completion
- 2021-09-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Regorafenib | Small molecule | 120 mg | Oral |
| Comparator | Tamoxifen | Small molecule | 40 mg | — |